Scholars Central

OtherPublished 23 Jul 2016

Rupatadine for the treatment of allergic rhinitis and urticaria: a look at the clinical data

Authors: Erminia Ridolo, Marcello Montagni, Filippo Fassio, Ilaria Massaro, Oliviero Rossi, Cristoforo Incorvaia & Giorgio Walter Canonica

Clinical Investigation

Volume 4 · Issue 5 · Pages 453–461

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

The second-generation antihistamine rupatadine is a new long-acting and non-sedating drug that exerts a potent dual-antagonist activity towards the histamine H1 receptor and the PAF receptor. Rupatadine is prescribed for the relief of symptoms of seasonal and perennial allergic rhinitis and in the treatment of chronic urticaria. Clinical trials have shown that rupatadine, which shows a rapid onset of action and prolonged duration of activity, is effective and well tolerated. Safety data indicate that rupatadine does not affect the cardiovascular system, without relevant changes in the corrected QT interval, or significantly affect psychomotor activity at the doses used in clinical practice. Here, we review the efficacy and safety profile of rupatadine in patients with allergic rhinitis and urticaria.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalClinical Investigation
  • SubjectGeneral & Internal Medicine
  • BylineArticles whose byline prints “Erminia Ridolo”
  • BylineArticles whose byline prints “Marcello Montagni”
  • BylineArticles whose byline prints “Filippo Fassio”
  • BylineArticles whose byline prints “Ilaria Massaro”
  • BylineArticles whose byline prints “Oliviero Rossi”
  • BylineArticles whose byline prints “Cristoforo Incorvaia & Giorgio Walter Canonica”